Related Experiment Videos
[Current status in the treatment of inoperable non-small cell lung cancer (NSCLC)]
Abstract:
Advances in the treatment of inoperable non-small cell lung cancer (NSCLC) have been falling behind the recent results obtained for small cell lung cancer (SCLC) which had been considered the more malignant type with the shortest survival time. Recently, however, with the introduction of cisplatin, the results of combination chemotherapy for NSCLC have shown a degree of advancement so that an average response rate of 40% and a median survival time (MST) of 8-10 months can be obtained. Our method of combination chemotherapy, PPM (cisplatin, peplomycin, mitomycin C), resulted in an overall response rate of 44% (40% squamous, 29% adeno, 64% large) and an MST of more than 23.3 months in responders. With PFM (cisplatin, 5FU, mitomycin C), response rate was 35% and an MST of 18.7 months was obtained for adenocarcinoma responders. It can therefore be said that we have achieved a new degree of success in the treatment in NSCLC.
Insights
New chemotherapy combinations, PPM and PFM, show improved treatment outcomes for inoperable non-small cell lung cancer (NSCLC). These regimens offer higher response rates and significantly longer median survival times for patients with advanced NSCLC.
Area of Science:
- Oncology
- Medical Chemistry
Context:
- Inoperable non-small cell lung cancer (NSCLC) treatment has lagged behind small cell lung cancer (SCLC).
- Cisplatin-based combination chemotherapy has recently improved NSCLC outcomes, yielding response rates around 40% and median survival times (MST) of 8-10 months.
Purpose:
- To evaluate the efficacy of two novel combination chemotherapy regimens, PPM (cisplatin, peplomycin, mitomycin C) and PFM (cisplatin, 5FU, mitomycin C), in treating inoperable non-small cell lung cancer.
Summary:
- The PPM regimen achieved an overall response rate of 44% (40% squamous, 29% adenocarcinoma, 64% large cell) with an MST exceeding 23.3 months in responders.
- The PFM regimen resulted in a 35% response rate, with responders achieving an MST of 18.7 months, particularly for adenocarcinoma.
Impact:
- These findings represent a significant advancement in the treatment of inoperable non-small cell lung cancer.
- The developed chemotherapy regimens offer improved therapeutic options and survival benefits for NSCLC patients.